Santgar

What Santgar does

Santgar, formally Laboratorio Santgar Fórmulas Magistrales de México, S.A. de C.V., is a Mexican veterinary pharmaceutical laboratory headquartered in Iztacalco, Ciudad de México. Established approximately 10 years ago, the company has positioned itself as a reference player in veterinary ophthalmology in Mexico, developing, manufacturing, and distributing proprietary pharmaceutical formulations for companion animals—canines, felines, and equines. The legal entity is a privately held Mexican corporation (S.A. de C.V.) with no disclosed parent company, institutional investors, or funding rounds.

The product portfolio centers on four core branded products: EXCENTERA LS (a patent-pending liposomal suspension of Sirolimus 0.4 mg/ml for immune-mediated keratoconjunctivitis sicca in canines), MEIBUX Ω3 (an ophthalmic emulsion with Omega-3 DHA/EPA for evaporative dry eye disease in canines and felines), NIONAR (sterile equine-derived ophthalmic discs used as surgical repair material for corneal lesions), and INODIL 5 MG (Pimobendan tablets for canine and feline congestive heart failure). The technical anchor is the proprietary liposomal delivery platform in EXCENTERA LS, which uses encapsulation to localize Sirolimus action, reduce adverse effects, and prolong drug residence time for immunomodulatory therapy.

Santgar operates a B2B distribution model through an authorized distributor network across Mexico, supplemented by direct engagement with veterinarians via a dedicated portal and the Santgar Insights content platform. A separate "Tutores" (pet owner) portal and the strategic partnership with Hospital Oftalvet provide demand-side and clinical service linkages. The company earns revenue through one-time sales of prescription veterinary pharmaceuticals and devices; no pricing, recurring subscription, or service revenue model is disclosed. Go-to-market is segmented by audience (veterinarians, distributors, pet owners) with educational content marketing (Insights blog, social media on Facebook, Instagram, and LinkedIn) as the primary awareness channel.

Name

Santgar

Legal name

Laboratorio Santgar Fórmulas Magistrales de México, S.A. de C.V.

Website

https://santgar.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

51–100 employees

Short description

Santgar is a Mexican veterinary pharmaceutical laboratory specializing in proprietary ophthalmology formulations for companion animals (canines, felines, equines), distributing branded products including liposomal Sirolimus and omega-3 ophthalmic emulsions through a nationwide authorized distributor network and veterinarian-direct channels.

Ownership category

akta.pro rank

Product category

Veterinary Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic & Private-Label Veterinary Pharmaceuticals (HLAMAEAM)

akta.pro secondary industries

Wound Care, Bandaging & Consumables (Dressings, Sutures, Staplers) (HLAMAFAF), Endocrinology & Metabolic Drugs (e.g., Diabetes, Thyroid) (HLAMAEAG)

Keywords

• Veterinary ophthalmology products
• Animal pharmaceutical formulations
• Ophthalmic medications pets
• Veterinary cardiology drugs
• Liposomal drug delivery

Headquarters

HQ city

Mexico City

HQ country

Mexico

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales

Revenue model

1. Veterinary Pharmaceutical Products: Santgar generates revenue through the sale of proprietary veterinary pharmaceutical products for ophthalmology and related conditions in companion animals. Products include prescription medications, medical devices, and nutritional supplements distributed through authorized veterinary distributors.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Santgar is a Mexican veterinary medical laboratory that designs, develops, manufactures, and distributes proprietary pharmaceutical formulations focused on veterinary ophthalmology and cardiology for companion animals (canines, felines, equines). Its product portfolio includes liposomal sirolimus suspensions, omega-3 ophthalmic emulsions, sterile equine-origin ophthalmic surgical discs, and pimobendan cardiac tablets, sold via an authorized distributor network across Mexico.

Product overview

Santgar is a Mexican veterinary ophthalmology laboratory that has developed a portfolio of pharmaceutical products specifically formulated for animal eye health. The product portfolio consists of four distinct core products: EXCENTERA LS® (liposomal sirolimus injection for immune-mediated eye conditions), MEIBUX Ω3® (omega-3 based ocular emulsion for dry eye syndrome), NIONAR® (equine-derived ophthalmic surgical discs for corneal repair), and INODIL® 5 MG (pimobendan cardiac medication for companion animals). These products serve both ophthalmological and cardiac therapeutic areas, addressing conditions in canines, felines, and equines.

Differentiator

Problem solved

Functional benefit

Products and services

• EXCENTERA LS® Liposomal injectable suspension containing Sirolimus 0.4 mg per ml, indicated for the treatment of immune-mediated keratoconjunctivitis sicca and control of immune-mediated ocular inflammatory disorders in canines. The liposomal delivery system promotes localized action, decreases adverse effects, and prolongs residence time of Sirolimus.
• MEIBUX Ω3® Ophthalmic emulsion containing Omega 3 (DHA and EPA) minimum 2.4 mg per ml, indicated for patients with dry eye disease associated with evaporative stress syndrome in canines and felines. Addresses quality deficiencies in the preocular film lipid components causing rapid evaporation and inadequate tear distribution.
• NIONAR® Sterile ophthalmic discs of equine origin, used as auxiliary surgical material in the repair of corneal surface lesions as a functional aid for restoration and healing of corneal integrity. Indicated for surgical use in repair of severe, deep corneal lesions and total ruptures in canines, felines, and equines.
• INODIL® 5 MG Positive inotropic tablet containing Pimobendan 5.0 mg, indicated for the treatment of canine congestive heart failure caused by chronic valvular disease or dilated cardiomyopathy, and for cats with heart failure with systolic ventricular dysfunction, significant pleural effusion, renal failure, or refractory pulmonary edema.

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Hospital OftalvetcoreStrategic or Co-development PartnerHospital Oftalvet is a key strategic partner providing veterinary ophthalmology services. Santgar directs pet owners to the hospital for specialized care and collaborates on the Veterinary Ophthalmology for the World (VOFTW) community platform, a global exclusive community for veterinarians interested in ophthalmology.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Virbac: Independent global animal health company with a meaningful companion animal specialty portfolio. Comparable to Santgar as a vet pharma manufacturer selling through veterinary channels, though at significantly larger scale.
• Elanco Animal Health: One of the largest global animal health companies, with a specialty companion animal portfolio strengthened by the Dechra acquisition. A direct competitive threat to Santgar in specialty vet ophthalmology worldwide.
• Vetoquinol: Independent French veterinary pharmaceutical group with specialty products across companion animals including ophthalmology. Comparable as a specialty-led vet pharma company serving veterinarians through prescription products in multiple geographies.
• Ceva Santé Animale: Global veterinary pharmaceutical company with strong presence in emerging markets and a growing specialty companion animal portfolio. Comparable as a vet pharma player expanding specialty ophthalmology and immunology products.
• MSD Animal Health (Merck Animal Health): Global animal health division of Merck with a broad pharmaceutical and biological portfolio for companion and production animals. Comparable as a global incumbent competing for specialty vet pharma share, including ophthalmology adjacencies.
• Zoetis: Largest global animal health company with a comprehensive companion animal portfolio including ophthalmology (e.g., cyclosporine products). Represents the dominant competitive benchmark for any specialty vet pharma including Santgar.
• Dechra Pharmaceuticals: Specialty veterinary pharmaceuticals company with strong portfolios in endocrine, ophthalmology (including cyclosporine-based ophthalmics) and other therapeutic niches. Highly comparable business model to Santgar as a focused vet pharma specialist, though materially larger and now part of Elanco.
• Phibro Animal Health: Animal health and nutrition company offering a mix of pharmaceuticals and nutritional specialties. Comparable as a vet pharma manufacturer serving companion and production animal segments.

Regional players

• Vetanco: Latin American animal health company headquartered in Argentina with presence across the region. Comparable to Santgar as a regional specialty animal health company serving veterinary channels in Latin America.
• Agrovet Market: Peruvian veterinary pharmaceutical company distributing animal health products across Latin America. Comparable as a regional vet pharma player building specialty portfolios in emerging Latin American markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/laboratorio.santgar
• LinkedInlinkedin.com/company/laboratorio-santgar
• Instagraminstagram.com/santgarmx
• Xx.com/lab_santgar

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Santgar